Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | AGXT | P21549 | 3/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1314001 | 0.88 | AGXT (0.42) | MAOBL3MBTL1MAPTSMN1; SMN2AGXT | |
| SCHEMBL11934179 | 0.85 | TP53 (0.42) | L3MBTL1MAPTRAB9ASMN1; SMN2AGXT | |
| SCHEMBL9347235 | 0.85 | ESR1 (0.43) | GAAMAPTIDO1SLC6A2 | |
| SCHEMBL14542685 | 0.85 | AGXT (0.43) | MAOBL3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL6617538 | 0.84 | MAOB (0.49) | MAOBMAOAGAARAB9ASMN1; SMN2 | |
| SCHEMBL4587307 | 0.84 | IDO1 (0.42) | MAOBL3MBTL1RAB9ASMN1; SMN2IDO1 | |
| SCHEMBL9347236 | 0.84 | AGXT (0.33) | MAOBSMN1; SMN2AGXTIDO1 | |
| SCHEMBL2745018 | 0.84 | PPARG (0.41) | — | |
| SCHEMBL6622204 | 0.83 | MAOB (0.47) | MAOBMAOAMAPTAGXTIDO1 | |
| SCHEMBL14546351 | 0.83 | SIGMAR1 (0.33) | L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4237008-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| US-11744897-B2 | Folate receptor targeted nanoparticle drug conjugates and uses thereof | ELUCIDA ONCOLOGY, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| CN-116669773-A | Method for functionalizing nanoparticles | 易达制药公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230263899-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| CN-116568335-A | Folate receptor targeted nanoparticle drug conjugate and application thereof | 易达制药公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20220378924-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2022-12-01 | — | — | US | disclosed |
| WO-2022093800-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20130172345-A1 | 1-ACYL-4-(PHENOXY, BENZYLOXY, OR PHENYLAMINO)-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES | KOWA COMPANY, LTD. (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20120196989-A1 | SYNTHESIS OF HOMOPOLYMERS AND BLOCK COPOLYMERS | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2012-08-02 | — | — | US | disclosed |
| EP-0708660-B1 | COMPOUNDS USEFUL FOR PREPARING PRODRUGS OF PROTEIN TYROSINE KINASE INHIBITORS | CANCER RES CAMPAIGN TECH (GB) | 2007-05-09 | — | — | EP | disclosed |
| US-6005002-A | Nitrogen mustard prodrugs with novel lipophilic protecting groups, and processes for their production | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-12-21 | — | — | US | disclosed |
| US-5770731-A | PROTECTING GROUPS, ANTIBODY DIRECTED ENZYME/PRODRUG THERAPY, ANTICARCINOGENIC AGENTS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-06-23 | — | — | US | disclosed |
| US-5728868-A | Prodrugs of protein tyrosine kinase inhibitors | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-03-17 | — | — | US | disclosed |
| EP-0804413-A1 | NITROGEN MUSTARD PRODRUGS WITH NOVEL LIPOPHILIC PROTECTING GROUPS, AND PROCESSES FOR THEIR PRODUCTION | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996022277-A1 | NITROGEN MUSTARD PRODRUGS WITH NOVEL LIPOPHILIC PROTECTING GROUPS, AND PROCESSES FOR THEIR PRODUCTION | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-07-25 | — | — | WO | disclosed |
| EP-0711177-A1 | IMPROVEMENTS RELATING TO PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-05-15 | — | — | EP | disclosed |
| EP-0708660-A1 | PRODRUGS OF PROTEIN TYROSINE KINASE INHIBITORS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995003830-A2 | PRODRUGS OF FARNESYL TRANSFERASE INHIBITORS FOR ADEPT OR VDEPT | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1995-02-09 | — | — | WO | disclosed |
| WO-1995002420-A2 | PRODRUGS OF PROTEIN TYROSINE KINASE INHIBITORS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LTD. (GB) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378924-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | FOLR1, FOLR2, DHFR | MAOB 1445/4885MAOA 1656/4885L3MBTL1 3328/4885 |
| US-20230263899-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | FOLR1, FOLR2, DHFR | MAOB 1445/4885MAOA 1656/4885L3MBTL1 3328/4885 |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | MAOB 2044/4885MAOA 1972/4885L3MBTL1 1936/4885 |
| US-11744897-B2 | Folate receptor targeted nanoparticle drug conjugates and uses thereof | FOLR1, FOLR2, DHFR | MAOB 1445/4885MAOA 1656/4885L3MBTL1 3328/4885 |
| US-20130172345-A1 | 1-ACYL-4-(PHENOXY, BENZYLOXY, OR PHENYLAMINO)-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES | EPOR, HBG2, HBG1 | MAOB 2332/4885MAOA 2476/4885L3MBTL1 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.